Immune changes and neurotransmitters: Possible interactions in depression?

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 48, Issue , 2014, Pages 268-276

  Sperner Unterweger, Barbara ^a   Kohl, Claudia ^a   Fuchs, Dietmar ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Depression; Inflammation; Interferon ; Oxidative stress; Phenylalanine; Tetrahydrobiopterin (BH4)

Indexed keywords

ADRENALIN; DOPAMINE; GAMMA INTERFERON; NEUROTRANSMITTER; NORADRENALIN; PHENYLALANINE; PHENYLALANINE 4 MONOOXYGENASE; REACTIVE OXYGEN METABOLITE; SEROTONIN; SEROTONIN RECEPTOR; TETRAHYDROBIOPTERIN; TYROSINE;

ADRENERGIC SYSTEM; AMINO ACID METABOLISM; ARTICLE; CATECHOLAMINE SYNTHESIS; CHRONIC INFLAMMATION; CYTOKINE RELEASE; DEPRESSION; DISEASE ASSOCIATION; ENDOCRINE FUNCTION; HORMONE SYNTHESIS; HYPERPHENYLALANINEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOLOGICAL MONITORING; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOSTIMULATION; MACROPHAGE; MAJOR DEPRESSION; MONOAMINE METABOLISM; NEUROTRANSMITTER RELEASE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PREVALENCE; SEROTONINERGIC SYSTEM;

5,6,7,8-TETRAHYDROBIOPTERIN; 5-HT; BH(4); DA; DEPRESSION; DOPAMINE; GCH; GTP CYLOHYDROLASE I; HIV; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUVEC; IDO; IFN-Α -SS -Γ; INDOLEAMINE 2,3-DIOXYGENASE; INFLAMMATION; INTERFERON-Α, -SS, -Γ; INTERFERON-Γ; KYN/TRP; KYNURENINE TO TRYPTOPHAN RATIO; L-3,4-DIHYDROXYPHENYLALANINE; L-DOPA; LIPOPOLYSACCHARIDE; LPS; NA; NET; NITRIC OXIDE; NO; NORADRENALINE; NOREPINEPHRINE TRANSPORTER; O(2)(-); ONOO(-); OXIDATIVE STRESS; PAH; PEROXINITRITE; PHE/TYR; PHENYLALANINE; PHENYLALANINE 4-HYDROXYLASE; PHENYLALANINE TO TYROSINE RATIO; PHENYLKETONURIA; PKU; REACTIVE OXYGEN SPECIES; ROS; SEROTONIN; SUPEROXIDE ANION; TDO; TETRAHYDROBIOPTERIN (BH4); TNF-Α; TRYPTOPHAN 2,3-DIOXYGENASE; TUMOR NECROSIS FACTOR-Α;

DEPRESSION; HUMANS; IMMUNE SYSTEM; NEUROTRANSMITTER AGENTS;

EID: 84888863015     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.10.006     Document Type: Article

References (115)

1. Anderson D.N., Wilkinson A.M., Abou-Saleh M.T., Blair J.A. Recovery from depression after electroconvulsive therapy is accompanied by evidence of increased tetrahydrobiopterin-dependent hydroxylation. Acta Psychiatr Scand 1994, 90:10-13.
2. Avanzas P., Arroyo-Espliguero R., Quiles J., Roy D., Kaski J.C. Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris. Eur Heart J 2005, 26:457-463.
3. Botez M.I., Young S.N., Bachevalier J., Gauthier S. Folate deficiency and decreased brain 5-hydroxytryptamine synthesis in man and rat. Nature 1979, 278:182-183.
4. Bottiglieri T., Laundy M., Crellin R., Toone B.K., Carney M.W., Reynolds E.H. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry 2000, 69:228-232.
5. Boushey C.J., Beresford S.A., Omenn G.S., Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J Am Med Assoc 1995, 274:1049-1057.
6. Braestrup C., Andersen H., Randrup A. The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation. Eur J Pharmacol 1975, 34(1):181-187.
7. Bromet E., Andrade L.H., Hwang I., Sampson N.A., Alonso J., De Girolamo G., et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med 2011, 9:90.
8. Bruce M.L., Seeman T.E., Merrill S.S., Blazer D.G. The impact of depressive symptomatology on physical disability: MacArthur studies of successful aging. Am J Public Health 1994, 84:1796-1799.
9. Bull S.J., Huezo-Diaz P., Binder E.B., Cubells J.F., Ranjith G., Maddock C., et al. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry 2008, 14:1095-1104.
10. Capuron L., Schroecksnadel S., Féart C., Aubert A., Higueret D., Barberger-Gateau P., et al. Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biol Psychiatry 2011, 70:175-182.
11. Caspi A., Sugden K., Moffitt T.E., Taylor A., Craig I.W., Harrington H., et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003, 301:386-389.
12. Celik C., Erdem M., Cayci T., Ozdemir B., Ozgur Akgul E., Kurt Y.G., et al. The association between serum levels of neopterin and number of depressive episodes of major depression. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:372-375.
13. Cervilla A., Molina E., Rivera M., Torres-Gonzalez F., Bellon J.A., Morena B., et al. The risk for depression conferred by stressful life events is modified by variation at the serotonin transporter 5HTTLPR genotype: evidence from the Spanish PREDICT-Gene cohort. Mol Psychiatry 2007, 12:748-755.
14. Chang X.J., Yang C.C., Hsu W.S., Xu W.Z., Shih T.S. Serum and erythrocyte amino acid pattern: studies on major burn cases. Burns Incl Therm Inj 1983, 9:240-248.
15. Charney D.S., Manji H.K. Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention. Sci STKE 2004, 2004(225):re5.
16. Connor M.J., Pheasant A.E., Blair J.A. The identification of p-acetamiobenzoate as a folate degradation product in rat urine. Biochem J 1979, 178:795-797.
17. Crabtree M.J., Channon K.M. Synthesis and recycling of tetrahydrobiopterin in endothelial function and vascular disease. Nitric Oxide 2011, 25:81-88.
18. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9:46-56.
19. Denz H., Fuchs D., Huber H., Nachbaur D., Reibnegger G., Thaler J., et al. Correlation between neopterin, interferon-gamma and haemoglobin in patients with haematological disorders. Eur J Haematol 1990, 44:186-189.
20. Devoino L., Morozova N., Cheido M. Participation of serotoninergic system in neuroimmunomodulation: intraimmune mechanisms and the pathways providing an inhibitory effect. Int J Neurosci 1988, 40(1-2):111-128.
21. Devoino L., Alperina E., Idova G. Dopaminergic stimulation of the immune reaction: interaction of serotoninergic and dopaminergic systems in neuroimmunomodulation. Int J Neurosci 1988, 40(3-4):271-288. [1988 Jun].
22. Du J., Teng R.J., Lawrence M., Guan T., Xu H., Ge Y., et al. The protein partners of GTP cyclohydrolase I in rat organs. PLoS One 2012, 7:e33991.
23. Eikelboom J.W., Lonn E., Genest J., Hankey G., Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999, 131:363-375.
24. Eley T.C., Sugden K., Corsico a., Gregory A.M., Sham P., McGuffin P., et al. Gene-environment interaction analysis of serotonin system markers with adolescent depression. Mol Psychiatry 2004, 9:908-915.
25. Farias M.S., Budni P., Ribeiro C.M., Parisotto E.B., Santos C.E., Dias J.F., et al. Antioxidant supplementation attenuates oxidative stress in chronic hepatitis C patients. Gastroenterol Hepatol 2012, 35:386-394.
26. Fuchs D., Möller A.A., Reibnegger G., Stöckle E., Werner E.R., Wachter H. Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J Acquir Immune Defic Syndr 1990, 3:873-876.
27. Fuchs D., Jäger M., Widner B., Wirleitner B., Artner-Dworzak E., Leblhuber F. Is hyperhomocysteinemia due to the oxidative depletion of folate rather than to insufficient dietary intake?. Clin Chem Lab Med 2001, 39:691-694.
28. Gotlib I.H., Joormann J., Minor K.L., Hallmayer J. HPA axis reactivity: a mechanism underlying the associations among 5-HTTLPR, stress, and depression. Biol Psychiatry 2008, 63:847-951.
29. Grammer T.B., Fuchs D., Boehm B.O., Winkelmann B.R., Maerz W. Neopterin as a predictor of total and cardiovascular mortality in individuals undergoing angiography in the Ludwigshafen Risk and Cardiovascular Health study. Clin Chem 2009, 55:1135-1146.
30. Halliwell B. Reactive oxygen species in living systems: source, biochemistry, and role in human disease. Am J Med 1991, 91:14S-22S.
31. Hansen M.S., Fink P., Frydenberg M., Oxhoj M., Sondergaard L., Munk-Jorgensen P. Mental disorders among internal medical inpatients: prevalence, detection, and treatment status. J Psychosom Res 2001, 50:199-204.
32. Harada T., Kagamiyama H., Hatakeyama K. Feedback regulation mechanisms for the control of GTP cyclohydrolase I activity. Science 1993, 260:1507-1510.
33. Hardman A., Maguire P., Crowther D. The recognition of psychiatric morbidity on a medical oncology ward. J Psychosom Res 1989, 33:235-239.
34. Haroon E., Raison C.L., Miller A.H. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2012, 37:137-162.
35. Harrison B.J., Olver J.S., Norman T.R., Nathan P.J. Effects of serotonin and catecholamine depletion on interleukin-6 activation and mood in human volunteers. Hum Psychopharmacol 2002, 17:293-297.
36. Harter M., Woll S., Reuter K., Wunsch A., Bengel J. Recognition of psychiatric disorders in musculoskeletal and cardiovascular rehabilitation patients. Arch Phys Med Rehabil 2004, 85:1192-1197.
37. Harter M., Baumeister H., Reuter K., Jacobi F., Höfler M., Bengel J., et al. Increased 12-month prevalence rates of mental disorders in patients with chronic somatic diseases. Psychother Psychosom 2007, 76:354-360.
38. Hashimoto R., Nagatsu T., Ohta T., Mizutani M., Omura I. Changes in the concentrations of tetrahydrobiopterin, the cofactor of tyrosine hydroxylase, in blood under physical stress and in depression. Ann N Y Acad Sci 2004, 1018:378-386.
39. Heller R., Unbehaun A., Schellenberg B., Mayer B., Werner-Felmayer G., Werner E.R. l-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem 2001, 276:40-47.
40. Herrmann W., Herrmann M., Obeid R. Hyperhomocysteinaemia: a critical review of old and new aspects. Curr Drug Metab 2007, 8:17-31.
41. Heyes M.P., Saito K., Crowley J.S., Davis L.E., Demitrack M.A., Der M., et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 1992, 115:1249-1273.
42. Hoffmann G., Wirleitner B., Fuchs D. Potential role of immune system activation associated production of neopterin derivatives in humans. Inflamm Res 2003, 52:313-321.
43. Holsboer F. How can we realize the promise of personalized antidepressant medicines?. Nat Rev Neurosci 2008, 9:638-646.
44. Hronek M., Zadak Z., Solichova D., Jandik P., Melichar B. The association between specific nutritional antioxidants and manifestation of colorectal cancer. Nutrition 2000, 16:189-191.
45. Hu B., Hissong B.D., Carlin J.M. Interleukin-1 enhances indoleamine 2,3-dioxygenase activity by increasing specific mRNA expression in human mononuclear phagocytes. J Interferon Cytokine Res 1995, 15:617-624.
46. Jabbi M., Korf J., Kema I.P., Hartman C., van der Pompe G., Minderaa R.B., et al. Convergent genetic modulation of the endocrine stress response involves polymorophic variations of 5-HTT, COMT and MAOA. Mol Psychiatry 2007, 12:483-490.
47. Kamata M., Suziki A., Yoshida K., Takahashi H., Higuchi H., Otani K. Genetic polymorphisms in the serotonergic system and symptom slusters of major depressive disorder. J Affect Disord 2011, 135:374-376.
48. Kapur S., Mann J.J. Role of the dopaminergic system in depression. Biol Psychiatry 1992, 32(1):1-17. [Jul 1].
49. Kaski J.C., Consuegra-Sanchez L., Fernandez-Berges D.J., Cruz-Fernandez J.M., Garcia-Moll X., Marrugat J., et al. Elevated serum neopterin levels and adverse cardiac events at 6months follow-up in Mediterranean patients with non-ST-segment elevation acute coronary syndrome. Atherosclerosis 2008, 201:176-183.
50. Kaufmann J., Yang B.Z., Douglas-Palumberi H., Houshyar S., Lipschitz D., Krystal J., et al. Social supports and serotonin transporter gene moderate deprssion in maltreated children. Proc Natl Acad Sci U S A 2004, 101:17316-17321.
51. Kim H., Lim S.W., Kim S., Kim J.W., Chang Y.H., Carroll B.J., et al. Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. J Am Med Assoc 2006, 296:1609-1618.
52. Kim Y.K., Na K.S., Shin K.H., Jung H.Y., Choi S.H., Kim J.B. Cytokine imbalance in the pathophysiology of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1044-1053.
53. Kohl C., Sperner-Unterweger B. IDO and clinical conditions associated with depressive symptoms. Curr Drug Metab 2007, 8:283-287.
54. Kuhn W., Roebroek R., Blom H., Van Oppenraaij D., Przuntek H., Kretschmer A., et al. Elevated plasma levels of homocysteine in Parkinson's disease. Eur Neurol 1998, 40:225-257.
55. Kuper H., Marmot M., Hemingway H. Systematic review of prospective cohort studies of psychosocial factors in the etiology and prognosis of coronary heart disease. Semin Vasc Med 2002, 2:267-314.
56. Leblhuber F., Walli J., Demel U., Tilz G.P., Widner B., Fuchs D. Increased serum neopterin concentrations in patients with Alzheimer's disease. Clin Chem Lab Med 1999, 37:429-431.
57. Leblhuber F., Walli J., Artner-Dworzak E., Vrecko K., Widner B., Reibnegger G., et al. Hyperhomocysteinemia in dementia. J Neural Transm 2000, 107:1469-1474.
58. Lindenbaum J., Healton E.B., Savage D.G., Brust J.C., Garrett T.J., Podell E.R., et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med 1988, 318:1720-1728.
59. Lotrich F.E., Ferrell R.E., Rabinovitz M., Pollock B.G. Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol Psychiatry 2009, 65:344-348.
60. Mathers C., Loncar D. Updated projection of global mortality and burden of disease, 2002-2030: data sources, methods and results 2005, WHO, Geneva.
61. Miller J.W. Homocysteine and Alzheimer's disease. Nutr Rev 1999, 57:126-129.
62. Milne G.L., Yin H., Hardy K.D., Davies S.S., Roberts L.J. Isoprostane generation and function. Chem Rev 2011, 111:5973-5996.
63. Moens A.L., Kass D.A. Therapeutic potential of tetrahydrobiopterin for treating vascular and cardiac disease. J Cardiovasc Pharmacol 2007, 50:238-246.
64. Montuschi P., Barnes P., Roberts L.J. Insights into oxidative stress: the isoprostanes. Curr Med Chem 2007, 14:703-717.
65. Murr C., Widner B., Wirleitner B., Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metab 2002, 3:175-187.
66. Murr C., Schroecksnadel K., Winklhofer-Roob B., Mangge H., Boehm B.O., Winkelmann B.R., et al. Inverse association between serum concentrations of neopterin and antioxidants in patients with and without angiographic coronary artery disease. Atherosclerosis 2009, 202:543-549.
67. Myint A.M., Schwarz M.J., Müller N. The role of the kynurenine metabolism in major depression. J Neural Transm 2012, 119:245-251.
68. Mynt A.M., Kim Y.K., Verkerk R., Scharpe S., Steinbusch H., Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord 2007, 98:143-151.
69. Nathan C.F., Murray H.W., Wiebe M.E., Rubin B.Y. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med 1983, 158:670-689.
70. Neurauter G., Grahmann A.V., Klieber M., Zeimet A., Ledochowski M., Sperner-Unterweger B., et al. Serum phenylalanine concentrations in patients with ovarian carcinoma correlate with concentrations of immune activation markers and of isoprostane-8. Cancer Lett 2008, 272:141-147.
71. Neurauter G., Schroecksnadel K., Scholl-Bürgi S., Sperner-Unterweger B., Schubert C., Ledochowski M., et al. Chronic immune stimulation correlates with reduced phenylalanine turnover. Curr Drug Metab 2008, 9:622-627.
72. Nourhashemi F., Gillette-Guyonnet S., Andrieu S., Ghisolfi A., Ousset P.J., Grandjean H., et al. Alzheimer disease: protective factors. Am J Clin Nutr 2000, 71:643S-649S.
73. Ollenschläger G., Jansen S., Schindler J., Rasokat H., Schrappe-Bächer M., Roth E. Plasma amino acid pattern of patients with HIV infection. Clin Chem 1988, 34:1787-1789.
74. Opladen T., Hoffmann G.F., Blau N. An international survey of patients with tetrahydrobiopterin deficiencies presenting with hyperphenylalaninaemia. J Inherit Metab Dis 2012, 35(6):963-973. [Epub ahead of print].
75. Ormel J., Petukhova M., Chatterji S., Aguilar-Gaxiola S., Alonso J., Angermeyer M.C., et al. Disability and treatment of specific mental and physical disorders across the world. Br J Psychiatry 2008, 192:368-375.
76. Parisi F., Kost-Byerly S., Saponara I., Di Donato R., Di Liso G. Elevated plasma homocysteine concentrations after pediatric heart transplantations. Transpl Int 2000, 13(Suppl. 1):S235-S239.
77. Penninx B.W., Guralnik J.M., Ferrucci L., Simonsick E.M., Degg D.J., Wallace R.B. Depressive symptoms and physical decline in community-dwelling older persons. J Am Med Assoc 1998, 279:1720-1726.
78. Ploder M., Neurauter G., Spittler A., Schroecksnadel K., Roth E., Fuchs D. Serum phenylalanine in patients post trauma and with sepsis correlate to neopterin concentrations. Amino Acids 2008, 35:303-307.
79. Ploder M., Schroecksnadel K., Spittler A., Neurauter G., Roth E., Fuchs D. Moderate hyperhomocysteinemia in patients with multiple trauma and with sepsis predicts poor survival. Mol Med 2010, 16:498-504.
80. Powers R.W., Evans R.W., Majors A.K., Ojimba J.I., Ness R.B., Crombleholme W.R., et al. Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation. Am J Obstet Gynecol 1998, 179:1605-1611.
81. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006, 27:24-31.
82. Rath T., Roth E., Keidl R., Meissl G. Phenylalanine: total amino acid ratio in 45 burn patients. Scand J Plast Reconstr Surg Hand Surg 1987, 21:297-300.
83. Romagnani S. T-cell responses in allergy and asthma. Curr Opin Allergy Clin Immunol 2001, 1:73-78.
84. Roth E., Zöch G., Schulz F., Karner J., Muehlbacher F., Hamilton G., et al. Amino acid concentrations in plasma and skeletal muscle of patients with acute hemorrhagic necrotizing pancreatitis. Clin Chem 1985, 31:1305-1309.
85. Ruhé H.G., Mason N.S., Schene A.H. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry 2007, 12:331-359.
86. Schroecksnadel K., Winkler C., Wirleitner B., Schennach H., Fuchs D. Anti-inflammatory compound resveratrol suppresses homocysteine formation in stimulated human peripheral blood mononuclear cells in vitro. Clin Exp Immunol 2005, 140:41-45.
87. Shintaku H. Disorders of tetrahydrobiopterin metabolism and their treatment. Curr Drug Metab 2002, 3:123-131.
88. Shiraishi H., Ikemoto K., Tada S., Udagawa Y., Ohtsuki M., Sumi-Ichinose C., et al. Cilostazol inhibits cytokine-induced tetrahydrobiopterin biosynthesis in human umbilical vein endothelial cells. J Atheroscler Thromb 2011, 18:312-317.
89. Sperner-Unterweger B., Neurauter G., Klieber M., Kurz K., Meraner V., Zeimet A., et al. Enhanced tryptophan degradation in patients with ovarian carcinoma correlates with several serum soluble immune activation markers. Immunobiology 2008, 216:296-301.
90. Spijker J., Graaf r., Bijl R.V., Beekman A.T., Omel J., Nolen W.A. Functional disability and depression in the general population. Results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Acta Psychiatr Scand 2004, 110:208-214.
91. Stabler S.P., Marcell P.D., Podell E.R., Allen R.H., Savage D.G., Lindenbaum J. Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry. J Clin Invest 1988, 81:466-474.
92. Stein D.J. Depression, anhedonia, and psychomotor symptoms: the role of dopaminergic neurocircuitry. CNS Spectr 2008, 13(7):561-565. [Jul].
93. Strik J.J., Lousberg R., Cheriex E.C., Honig A. One year cumulative incidence of depression following myocardial infarction and impact on cardiac outcome. J Psychosom Res 2004, 56:59-66.
94. Surtees P.G., Wainwright N.W., Willis-Owen S.aA., Luben R., Day N.E., Flint J. Social adversity, the serotonin transporter (5-HTTLPR) polymorphism and major depressive disorder. Biol Psychiatry 2006, 59:224-229.
95. Tatzber F., Rabl H., Koriska K., Erhart U., Puhl H., Waeg G., et al. Elevated serum neopterin levels in atherosclerosis. Atherosclerosis 1991, 89:203-208.
96. Trefz F.K., Scheible D., Frauendienst-Egger G., Korall H., Blau N. Long-term treatment of patients with mild and classical PKU by BH4. Mol Genet Metab 2005, 86:S75-S80.
97. Uher R., McGuffin P. The moderation by the serotonin transporter gene of environmental adversity in the aetiology of mental illness: review and methodological analysis. Mol Psychiatry 2008, 13:131-146.
98. Üstün T.B., Ayuso-Mateos J.L., Chatterji S., Mathers C., Murray C.J. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004, 184:386-392.
99. Van Gool A.R., Fekkes D., Kruit W.H., Mulder P.G., Ten Hagen T.L., Bannink M., et al. Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients. Psychiatry Res 2003, 119:125-132.
100. Van Gool A.R., van Ojik H.H., Kruit W.H., Bannink M., Mulder P.G., Eggermont A.M., et al. Pegylated interferon-alpha2b treatment in melanoma patients: influence on amino acids, 5-hydroxyindolacetic acid and pteridine plasma concentrations. Anticancer Drugs 2004, 15:587-591.
101. Wancata J., Windhaber J., Bach M., Meise U. Recognition of psychiatric disorders in nonpsychiatric hospital wards. J Psychosom Res 2000, 48:149-155.
102. Watanabe A., Higashi T., Sakata T., Nagashima H. Serum amino acid levels in patients with hepatocellular carcinoma. Cancer 1984, 54:1875-1882.
103. Watschinger K., Keller M.A., Golderer G., Hermann M., Maglione M., Sarg B., et al. Identification of the gene encoding alkylglycerol monooxygenase defines a third class of tetrahydrobiopterin-dependent enzymes. Proc Natl Acad Sci U S A 2010, 107:13672-13677.
104. Werner-Felmayer G., Golderer G., Werner E.R. Tetrahydrobiopterin biosynthesis, utilization and pharmacological effects. Curr Drug Metab 2002, 3:159-173.
105. Widner B., Ledochowski M., Fuchs D. Interferon-gamma-induced tryptophan degradation: neuropsychiatric and immunological consequences. Curr Drug Metab 2000, 1:193-204.
106. Widner B., Fuchs D., Leblhuber F., Sperner-Unterweger B. Does disturbed homocysteine and folate metabolism in depression result from enhanced oxidative stress?. J Neurol Neurosurg Psychiatry 2001, 70:419.
107. Widner B., Enzinger C., Laich A., Wirleitner B., Fuchs D. Hyperhomocysteinemia, pteridines and oxidative stress. Curr Drug Metab 2002, 3:225-232.
108. Widner B., Laich A., Sperner-Unterweger B., Ledochowski M., Fuchs D. Neopterin production, tryptophan degradation, and mental depression - what is the link?. Brain Behav Immun 2002, 16:590-595.
109. Widner B., Leblhuber F., Fuchs D. Increased neopterin production and tryptophan degradation in advanced Parkinson's disease. J Neural Transm 2002, 109:181-189.
110. Wilhelm K., Mitchell P.B., Niven H., Finch A., Wedgwood L., Scimone A., et al. Life events, first depression onset and the serotonin transporter gene. Br J Psychiatry 2006, 188:210-215.
111. Winkler C., Schroecksnadel K., Schennach H., Fuchs D. Vitamin C and E suppress mitogen-stimulated peripheral blood mononuclear cells in vitro. Int Arch Allergy Immunol 2007, 142:127-132.
112. Wirleitner B., Neurauter G., Schroecksnadel K., Frick B., Fuchs D. Interferon-gamma-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr Med Chem 2003, 10:1581-1591.
113. Wirleitner B., Schroecksnadel K., Winkler C., Schennach H., Fuchs D. Resveratrol suppresses interferon-gamma-induced biochemical pathways in human peripheral blood mononuclear cells in vitro. Immunol Lett 2005, 100:159-163.
114. Zangerle R., Kurz K., Neurauter G., Kitchen M., Sarcletti M., Fuchs D. Increased blood phenylalanine to tyrosine ratio in HIV-1 infection and correction following effective antiretroviral therapy. Brain Behav Immun 2010, 24:403-408.
115. Zoller H., Schloegl A., Schroecksnadel S., Vogel W., Fuchs D. Interferon-alpha therapy in patients with hepatitis C virus infection increases plasma phenylalanine and the phenylalanine to tyrosine ratio. J Interferon Cytokine Res 2012, 32:216-220.